Infectious diseases, including bacterial, fungal, and viral, have once again gained urgency in the drug development pipeline after the recent COVID-19 pandemic. Tuberculosis (TB) is an old infectious disease for which eradication has not yet been successful. Novel agents are required to have potential activity against both drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis (Mtb), the causative agent of TB. In this study, we present a series of 2-phenyl-N-(pyridin-2-yl)acetamides in an attempt to investigate their possible antimycobacterial activity, cytotoxicity on the HepG2 liver cancer cell line, and-as complementary testing-their antibacterial and antifungal properties against a panel of clinically important pathogens. This screening resulted in one compound with promising antimycobacterial activity-compound 12, MICMtb H37Ra = 15.625 μg/mL (56.26 μM). Compounds 17, 24, and 26 were further screened for their antiproliferative activity against human epithelial kidney cancer cell line A498, human prostate cancer cell line PC-3, and human glioblastoma cell line U-87MG, where they were found to possess interesting activity worth further exploration in the future.

Biomedical Research Centre University Hospital Hradec Kralove Hradec Králové Czech Republic

Department of Clinical Microbiology University Hospital Hradec Králové Czech Republic

Faculty of Pharmacy in Hradec Králové Charles University Hradec Králové Czech Republic

Zobrazit více v PubMed

Araújo‐Mariz, C. , Lopes E. P., Acioli‐Santos B., et al. 2016. “Hepatotoxicity During Treatment for Tuberculosis in People Living With HIV/AIDS.” PLoS One 11, no. 6: e0157725. 10.1371/journal.pone.0157725. PubMed DOI PMC

Cadilla, R. H. , Richard B., Lambert M. H. III, Liu G. K., and Smith J. S.. 2003. “Preparation of Phenoxyalkanoic Acid Derivatives as hPPAR Activators for Treatment of Diabetes and Cardiovascular Diseases.” WO2003074495 (WO2003‐US5953).

Edwards, B. D. , Mah H., Sabur N. F., and Brode S. K.. 2023. “Hepatotoxicity and Tuberculosis Treatment Outcomes in Chronic Liver Disease.” Journal of the Association of Medical Microbiology and Infectious Disease Canada 8, no. 1: 64–74. 10.3138/jammi-2022-0029. PubMed DOI PMC

EUCAST . 2020a. “Definitive Document E.DEF 7.3.2. Method for the Determination of Broth Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Yeasts.” https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/EUCAST_E_Def_7.3.2_Yeast_testing_definitive_revised_2020.pdf. PubMed

EUCAST . 2020b. “Definitive Document E.DEF 9.3.2. Method for the Determination of Broth Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Conidia Forming Moulds.” https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/EUCAST_E_Def_9.3.2_Mould_testing_definitive_revised_2020.pdf. PubMed

European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) . 2003. “Determination of Minimum Inhibitory Concentrations (MICs) of Antibacterial Agents by Broth Dilution.” Clinical Microbiology and Infection 9, no. 8: ix–xv. 10.1046/j.1469-0691.2003.00790.x. DOI

Franzblau, S. G. , Witzig R. S., McLaughlin J. C., et al. 1998. “Rapid, Low‐Technology MIC Determination With Clinical Mycobacterium tuberculosis Isolates by Using the Microplate Alamar Blue Assay.” Journal of Clinical Microbiology 36, no. 2: 362–366. 10.1128/JCM.36.2.362-366.1998. PubMed DOI PMC

Kerda, M. , Šlechta P., Jand'ourek O., et al. 2023. “ N‐Pyrazinylhydroxybenzamides as Biologically Active Compounds: A Hit‐Expansion Study and Antimicrobial Evaluation.” Future Medicinal Chemistry 15: 1791–1806. 10.4155/fmc-2023-0189. PubMed DOI

Lange, C. , Abubakar I., Alffenaar J. W. C., et al. 2014. “Management of Patients With Multidrug‐Resistant/Extensively Drug‐Resistant Tuberculosis in Europe: A TBNET Consensus Statement.” European Respiratory Journal 44, no. 1: 23–63. 10.1183/09031936.00188313. PubMed DOI PMC

Molla, Y. , Wubetu M., and Dessie B.. 2021. “Anti‐Tuberculosis Drug Induced Hepatotoxicity and Associated Factors Among Tuberculosis Patients at Selected Hospitals, Ethiopia.” Hepatic Medicine: Evidence and Research 13: 1–8. 10.2147/HMER.S290542. PubMed DOI PMC

Nawrot, D. , Suchánková E., Janďourek O., et al. 2021. “N‐Pyridinylbenzamides: An Isosteric Approach Towards New Antimycobacterial Compounds.” Chemical Biology & Drug Design 97, no. 3: 686–700. 10.1111/cbdd.13804. PubMed DOI

Schön, T. , Werngren J., Machado D., et al. 2020. “Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis Complex Isolates—The EUCAST Broth Microdilution Reference Method for MIC Determination.” Clinical Microbiology and Infection 26, no. 11: 1488–1492. 10.1016/j.cmi.2020.07.036. PubMed DOI

World Health Organization . 2022. Global Tuberculosis Report, 2023. Geneve, Switzerland: WHO.

Zitko, J. , Mindlová A., Valášek O., et al. 2018. “Design, Synthesis and Evaluation of N‐Pyrazinylbenzamides as Potential Antimycobacterial Agents.” Molecules 23, no. 9: 2390. 10.3390/molecules23092390. PubMed DOI PMC

Zitko, J. , Servusová B., Paterová P., et al. 2013. “Synthesis, Antimycobacterial Activity and in Vitro Cytotoxicity of 5‐Chloro‐N‐Phenylpyrazine‐2‐Carboxamides.” Molecules 18, no. 12: 14807–14825. 10.3390/molecules181214807. PubMed DOI PMC